The decrease in EPS from $(0.82) to $(1.15) suggests that Protagenic Therapeutics experienced a decline in profitability over the fiscal year. This is a critical metric for investors as EPS is a direct indicator of a company's profitability and financial health. The significant drop in EPS is likely to be viewed negatively by the market, potentially leading to a decrease in stock price in the short term.